SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of
November 2008
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home
country exchange on which the registrant’s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with
Rule 12g3-2(b): 82 -
 |
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Investigators Present Interim
U.S. REOLYSIN® Phase II Sarcoma Trial Data
CALGARY,
AB, — November 6, 2008 — Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
announced today that an oral presentation covering the interim results of a U.S. Phase II trial
investigating intravenous REOLYSIN® in patients with bone and soft tissue sarcomas
metastatic to the lung is being delivered today by Dr. Monica Mita of the Institute of Drug
Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science
Center, (UTHSC), San Antonio, Texas at the Chemotherapy Foundation Symposium XXVI, which is being
held in New York from November 4-8, 2008.
“REOLYSIN® is a very well tolerated treatment that is also showing promising results in
patients with metastatic sarcoma,” said Dr. Mita. “We are pleased with the results and honored to
present the data at major meetings.”
To date, 35 patients have been enrolled in the study, and 29 are evaluable. 21% (6/29) of the
evaluable patients experienced stable disease (SD) for more than 16 weeks. The investigators
concluded that the study has met its established objectives, and that enrolment will continue to
the full 52 patients.
| |
|
|
|
|
| Tumour Type |
|
Cycles |
|
Best Response |
Synovial sarcoma |
|
17* |
|
SD |
Ewing’s sarcoma |
|
9* |
|
SD |
Malignant Fibrous Histiocytoma |
|
7* |
|
SD, tumor resection after cycle 4 |
Leiomyosarcoma |
|
6 |
|
SD |
Chordoma |
|
5* |
|
SD |
Unspecified Spindle Cell |
|
5* |
|
SD |
|
|
|
| * |
|
patients still on study |
An oral presentation covering results of the trial (REO 014) is also scheduled to be delivered at
the Connective Tissue Oncology Society (CTOS) annual meeting, being held in London, U.K. from
November 13-15, 2008.
The slides will be available on the Oncolytics’ website after the presentation.
Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research is also scheduled to present a
poster at the CTOS meeting entitled “Systemic Administration of REOLYSIN Inhibits Growth of Human
Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation.”
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication
of the materials presented at this meeting with respect to REOLYSIN®, the Company’s
expectations related to the results of trials investigating delivery of REOLYSIN®, the
Company’s analysis of the results of the Phase II trial, and the Company’s belief as to the
potential of REOLYSIN® as a cancer therapeutic, involve known and unknown risks and
uncertainties, which could cause the Company’s actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development projects, the efficacy of
REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies
and trials, the Company’s ability to successfully commercialize REOLYSIN®, uncertainties
related to the research and development of pharmaceuticals, uncertainties related to the regulatory
process and general changes to the economic environment. Investors should consult the Company’s
quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as required by applicable laws.
FOR FURTHER INFORMATION PLEASE CONTACT:
| |
|
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group
|
|
The Investor Relations Group |
Cathy Ward
|
|
Nick Hurst
|
|
Erika Moran |
210, 1167 Kensington Cr NW
|
|
325, 300 5th Ave. SW
|
|
11 Stone St, 3rd Floor |
Calgary, Alberta T2N 1X7
|
|
Calgary, Alberta, T2P 3C4
|
|
New York, NY 10004 |
Tel: 403.670.7377
|
|
Tel: 403.538.4845
|
|
Tel: 212.825.3210 |
Fax: 403.283.0858
|
|
Fax: 403.237.6916
|
|
Fax: 212.825.3229 |
cathy.ward@oncolytics.ca
|
|
nhurst@equicomgroup.com
|
|
emoran@investorrelationsgroup.com |
-30-